A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Trial Profile

A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Trigriluzole (Primary)
  • Indications Spinocerebellar ataxias
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceutical Holding Company
  • Most Recent Events

    • 06 Mar 2018 According to a Biohaven Pharmaceutical Holding Company media release, the FDA has expressed willingness to accept a modification of the trial's primary endpoint, the Scale for Assessment and Rating of Ataxia (also called SARA) as an acceptable registrational endpoint for the further development of trigriluzole in ataxias.
    • 02 Oct 2017 According to a Biohaven Pharmaceutical Holding Company media release, topline data from the extension phase are expected in 4Q2018.
    • 02 Oct 2017 Top-line results presented in a Biohaven Pharmaceutical media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top